Domainex today announced a potent lead compound in a model of COPD and has also won a £1.4m Biomedical Catalyst Award for Phase I clinical studies
9th July 2014
1st June 2014
Domainex Ltd. has successfully completed in-vivo studies examining its proprietary selective inhibitors of IKK-epsilon and TBK1 in inflammation models.
7th April 2014
Domainex programme shows great promise for the treatment of inflammatory diseases, such as Chronic Obstructive Pulmonary Disease (COPD).
5th November 2013
Domainex CSO, Prof Laurence Pearl, wins prestigious CRUK Translational Research Award
2nd September 2013
Domainex, a drug discovery CRO, awards Prof. Vilmos Fulop at University of Warwick with Discovery STAR Award for research in Chagas Disease treatment.
14th February 2013
Cambridge, UK, 14th February 2013.
22nd January 2013
Cambridge, UK: Domainex Ltd, specialists in drug discovery solutions and translational research support, has today announced that it is launching its
5th November 2012
Domainex Ltd has developed a number of chemical series with potent and selective activity against two closely related kinases TBK1 and IKK- epsilon.
6th August 2012
Domainex and Horizon announce collaboration in support of Domainex's TBK1/IKKe Inhibitor Program.
2nd August 2012
Domainex successful in securing Biomedical Catalyst Feasibility Award